Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TROPION-Urothelial04: Dato-DXd ± rilvegostomig vs standard of care as adjuvant therapy in high-risk muscle-invasive urothelial carcinoma
CTR20263090Phase 3Active
- Sponsor
- AstraZeneca
- Start
- Jul 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of datopotamab deruxtecan, rilvegostomig in urothelial carcinoma (MIBC), sponsored by AstraZeneca. Started Jul 2026; status: active.
02
Drugs
datopotamab deruxtecanrilvegostomig
03
Conditions
urothelial carcinoma (MIBC)
Beyond the preview
Go deeper on CTR20263090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263090.